Abbott COO Succession: Leiden Leaves, Gonzalez Takes Over Pharma Group
Executive Summary
Abbott Pharmaceutical Products Group President & COO Jeffrey Leiden's experience overseeing the Knoll acquisition could make the exec a particularly attractive candidate in the current climate of increasing M&A activity
You may also be interested in...
Abbott Gears Up For New Cholesterol Therapies, Winds Down Diagnostics
Building on two strategic initiatives announced last year - the acquisition of Kos and a collaboration with AstraZeneca - Abbott is gearing up to expand its commercial presence and late-stage pipeline in the cholesterol treatment market this year, President and Chief Operating Officer Richard Gonzalez said during the company's year-end sales and earnings call Jan. 24
Abbott Gears Up For New Cholesterol Therapies, Winds Down Diagnostics
Building on two strategic initiatives announced last year - the acquisition of Kos and a collaboration with AstraZeneca - Abbott is gearing up to expand its commercial presence and late-stage pipeline in the cholesterol treatment market this year, President and Chief Operating Officer Richard Gonzalez said during the company's year-end sales and earnings call Jan. 24
Bristol Interim CEO Pick Fuels Acquisition Rumors, Complicating Search
Bristol-Myers Squibb's search for a new CEO may be complicated by the widespread belief that the company is an acquisition target